AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.

While AI models like Google DeepMind's AlphaFold have revolutionized protein structure prediction, creating a flood of potential drug candidates, a critical bottleneck has emerged in actually characterizing these molecules for testing and production. 10x Science, founded in December 2025 by Stanford biochemists David Roberts, Andrew Reiter, and AI expert Vishnu Tejas, just secured $4.8 million in seed funding to tackle this problem. Their platform addresses the essential but slow process of molecular characterization through mass spectrometry—a technique that determines atomic structure but generates complex data requiring significant expertise to interpret.

10x's solution combines deterministic algorithms rooted in chemistry with AI agents specifically trained on spectrometry data. The platform automates data interpretation while maintaining traceability, a crucial requirement for regulatory compliance in drug development. Early users like Rilas Technologies scientist Matthew Crawford report the AI can autonomously search databases for protein sequences and explain its conclusions, significantly speeding up analysis. The startup is already working with major pharmaceutical companies and academic researchers, using the funding to hire engineers and refine their model for broader adoption in the $2 trillion biopharma industry.